课题基金 / 基金详情

IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling

IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
批准号:
10205742
负责人:
OFER LEVY
金额:
$80.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-01-28 至 2023-06-30

项目摘要

项目成果

OFER LEVY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC): Clinical and Data Coordinating Center (CDCC) Project summary In December 2019, a cluster of respiratory illness in Wuhan, China defined the onset of a global pandemic involving a novel coronavirus (SARS-CoV-2) with associated respiratory disease (COVID-19). There are major research efforts underway to understand SARS-CoV-2 infections and the associated COVID-19 disease. The IMmunoPhenotyping Assessment Covid-19 Cohort (IMPACC) surveillance study is based upon an observational cohort that will collect detailed clinical, laboratory, and radiographic data in coordination with biologic sampling of blood and respiratory secretions and viral shedding in nasal secretions. The goal of the surveillance study is to identify immunophenotypic and genomic features of COVID-19-related susceptibility and/or progression. The IMPACC Clinical and Data Coordinating Center (CDCC) will provide clinical and data coordination support for the IMPACC study. This includes comprehensive study coordination and project management support across all participating IMPACC clinical and Core laboratory sites, including initial site training and ongoing study support through the completion of study enrollment and follow-up. The CDCC will provide clinical sites with real-time sample tracking and data capture capabilities, including all necessary supplies and reagents for sample collection, electronic case report forms (eCRFs) for data entry, and quality control/quality assurance (QC/QA) processes to ensure high quality sample collection and data capture. Finally, the CDCC will design digital infrastructure components to facilitate data management, data storage, and data analysis of study endpoint and safety data, including interim and final analysis of primary endpoints, ongoing safety and outcome monitoring, and bioinformatics analytic support for secondary/exploratory endpoints.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
  • 批准号:
    10435035
  • 项目类别:
  • 资助金额:
    $166.59万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
  • 批准号:
    10589826
  • 项目类别:
  • 资助金额:
    $22.79万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
  • 批准号:
    10435043
  • 项目类别:
  • 资助金额:
    $19.86万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
  • 批准号:
    10589800
  • 项目类别:
  • 资助金额:
    $154.65万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
海外基金